Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn`s Disease

Study:

A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn`s Disease

Rationale:

n/a

Purpose:

The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn`s Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Crohn`s Disease Drug: Epanova™ (Omega-3 Free Fatty Acids) Phase 3

Verified by Tillotts Pharma AG October, 2005

Sponsored by: Tillotts Pharma AG
Information provided by: Tillotts Pharma AG
ClinicalTrials.gov identifier: NCT00074542

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site